fig4
Figure 4. Copper ionophores and cuproptosis combat tumor drug resistance. Copper ionophore elesclomol overcomes cisplatin, 5-fluorouracil and vemurafenib resistance in the indicated cancers. Copper ionophore disulfiram bypasses cisplatin, 5-fluorouracil, paclitaxel and gemcitabine resistance in the indicated tumors. Cuproptosis inducers combat cisplatin, proteasome inhibitors, oxaliplatin, docetaxel, enzalutamide and anti-PD-L1 resistance in the indicated cancers. PD-L1: CD274 molecule.
